Introduction
Patients and methods
Patients
Pathological evaluation after neoadjuvant therapy
Parameters in peripheral blood
Statistical analysis
Results
Clinical characteristics
Characteristics (n = 64) | N (%) |
---|---|
Age (years)a | |
≤ 62 | 34 (53.1) |
> 62 | 30 (46.9) |
ECOG-PS | |
0 | 20 (31.3) |
1 | 44 (68.7) |
Gender | |
Male | 50 (78.1) |
Female | 14 (21.9) |
Smoking | |
Yes | 37 (57.8) |
No | 27 (42.2) |
T stage | |
T1–T2 | 8 (12.5) |
T3–T4 | 56 (87.5) |
N stage | |
N0 | 20 (31.3) |
N1–N2 | 44 (68.7) |
Clinical stage | |
II | 19 (29.7) |
III | 33 (51.6) |
IV | 12 (18.7) |
CAP/NCCN pathological tumor regression grade | |
0 | 27 (42.2) |
1 | 14 (21.8) |
2 | 11 (17.2) |
3 | 12 (18.8) |
pCR (n) (%) | non-pCR (n) (%) | P value | |
---|---|---|---|
BMI | 0.136 | ||
Underweight, | 3 (33.3) | 6 (66.7) | |
Normal weight | 22 (50.0) | 22 (50.0) | |
Overweight | 2 (18.2) | 9 (81.8) | |
ECOG-PS | 0.432 | ||
0 | 7 (35.0) | 13 (65.0) | |
1 | 20 (45.5) | 24 (54.5) | |
Clinical stage | 0.742 | ||
II | 9 (47.4) | 10 (52.6) | |
III | 14 (42.4) | 19 (57.6) | |
IV | 4 (33.3) | 8 (66.7) | |
Tumor site | 0.945 | ||
Upper | 1 (33.3) | 2 (66.7) | |
Middle | 13 (43.3) | 17 (56.7) | |
Lower | 13 (41.9) | 18 (58.1) |
Association between response to anti‑PD‑1 plus chemotherapy and NLR at baseline and post-treatment
Response (n) | No response (n) | |
---|---|---|
NLR at baseline | ||
≤ 1.622 | 7 | 1 |
> 1.622 | 44 | 11 |
LMR at baseline | ||
≤ 3.173 | 19 | 0 |
> 3.173 | 32 | 12 |
PLR at baseline | ||
≤ 71.108 | 3 | 0 |
> 71.108 | 48 | 12 |
S II at baseline | ||
≤ 559.266 | 32 | 12 |
> 559.266 | 19 | 0 |
LMR at post treatment of second period | ||
≤ 5.987 | 46 | 11 |
> 5.987 | 6 | 1 |
LMR at post treatment of third period | ||
≤ 3.040 | 28 | 2 |
> 3.040 | 18 | 8 |
PLR at post treatment of third period | ||
≤ 151.516 | 22 | 10 |
> 151.516 | 24 | 1 |
S II at post treatment of second period | ||
≤ 174.574 | 9 | 1 |
> 174.574 | 43 | 11 |
BMI | ||
Underweight, | 8 | 1 |
Normal weight | 36 | 8 |
Overweight | 8 | 3 |
ECOG-PS | ||
0 | 14 | 5 |
1 | 38 | 7 |
Clinical stage | ||
II | 15 | 4 |
III | 26 | 7 |
IV | 11 | 1 |
Tumor site | ||
Upper | 3 | 0 |
Middle | 22 | 8 |
Lower | 27 | 4 |
Association between response to anti‑PD‑1 plus chemotherapy and LMR at baseline and post-treatment
Association between response to anti‑PD‑1 plus chemotherapy and PLR at baseline and post-treatment
Association between response to anti‑PD‑1 plus chemotherapy and SII at baseline and post-treatment
Association between response to anti‑PD‑1 plus chemotherapy and the model of combining eight serum inflammation indexes
OR (95% CI) | P value | |
---|---|---|
LMR at baseline | ||
≤ 3.173 | 1.00 | |
> 3.173 | 3.881E8 (0.000-) | 0.998 |
S II at post treatment of second period | ||
≤ 174.574 | 1.00 | |
> 174.574 | 9.563E8 (0.000-) | 0.999 |
PLR at post treatment of third period | ||
≤ 151.516 | 1.00 | |
> 151.516 | 0.083 (0.009–0.782) | 0.030 |